Search Results - therapeuticarea+%3e+oncology

577 Results Sort By:
In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract
This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled...
Published: 12/26/2024   |   Inventor(s): Liping Zhang, Kelly Ten Hagen
Keywords(s): FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX
Category(s): TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Cardiology
Machine Learning Model for the Prioritization of Cancer Neoepitopes
Summary: The National Cancer Institute (NCI) seeks licensees for a machine learning algorithm that scores epitopes for likelihood of reactivity in order to create personalized effective immunotherapy. Description of Technology: Success in immunotherapy is often attributable to the reactivity of patient T-cells to specific mutated peptide(s) found...
Published: 12/20/2024   |   Inventor(s): Jared Gartner, Paul Robbins, Steven Rosenberg
Keywords(s):  
Category(s): Application > Research Materials, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Fully Human Chimeric Antigen Receptors Against CD276 for the Treatment of Solid Tumors
Summary: The National Cancer Institute (NCI) seeks research co-development partners and licensees for a panel of five fully human antibodies against CD276 for the treatment of solid tumors. The collection also includes human CARs incorporating the antibodies for immunotherapeutic use. Description of Technology: Chimeric antigen receptor (CAR)-T...
Published: 12/20/2024   |   Inventor(s): Brad St. Croix, Pradip Bajgain, Yang Feng
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing
Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...
Published: 12/9/2024   |   Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley
Keywords(s):  
Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins
Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers. Description of Technology: Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include...
Published: 12/20/2024   |   Inventor(s): Kylie Walters, Xiuxiu Lu
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing
NeoExpansion – A Method to Identify and Selectively Expand Neoantigen-specific T Cells, Including T Cell Receptor-engineered T Cells and Tumor Infiltrating Lymphocytes
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a method of identifying and selectively expanding neoantigen-specific T cells. Description of Technology: Somatic mutations are spontaneous changes in the DNA sequence of somatic cells which drive the development of most cancers. These somatic mutations...
Published: 12/20/2024   |   Inventor(s): Noam Levin, Sanghyun (Peter) Kim, Lior Levy, Steven Rosenberg
Keywords(s):  
Category(s): Collaboration Sought > Collaboration, ResearchProducts, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing
HLA-class II-restricted T Cell Receptors for PIK3CA “Hotspot” Mutations, E545K and N345K
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target PIK3CA mutations to treat patients with tumors expressing these mutations in the context of HLA-DPA1*01:03:01, HLA-DPB1*04:01:01 or HLA-DRB1*04:01. Description of Technology: Phosphatidylinositol-4,5-biphosphate...
Published: 12/20/2024   |   Inventor(s): Steven Rosenberg, NIkolaos Zacharakis, S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank Lowery
Keywords(s):  
Category(s): TherapeuticArea, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing
Novel Kinase Inhibitory Thiazines
Summary The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 12/20/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Rare / Neglected Diseases, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing
Reverse Thiazine Kinase Inhibitors
Summary The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 12/19/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Collaboration Sought > Licensing
Novel Kinase Inhibitory Aplithianines
Summary The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including: Oncogenic gene fusion DNAJB1-PRKACA (PKADJ) Wild type protein kinase A (PKA) Protein kinase...
Published: 12/20/2024   |   Inventor(s): Barry O'Keefe, Lin Du, Brice Wilson, Ping Zhang, William Moore, Dongdong Wang, Juliana Martinez Fiesco, Ning Li
Keywords(s):  
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
1 2 3 4 5 6 7 8 9 10 ...